Silvio Nocco

24PUBLICATIONS
67CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Exercise physiologyCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 12, 2026
Heart-Type Fatty Acid-Binding Protein (H-FABP) as a Candidate Adjunctive Biomarker for Immune Checkpoint Inhibitor-Related Cardiotoxicity: Linking Early Immune-Metabolic Myocardial Injury with Translational Cardio-Oncology.

|May 04, 2026
SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia.

|Feb 26, 2026
Metabolomic Signatures and Advanced Echocardiography Highlight Clinical Risk and Early Cardiac Changes in Systemic Lupus Erythematosus: Six-Year Follow-Up.

Nicola Campana, Michele Migliari, Antonio Deidda

|Jul 29, 2025
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway Inhibition.

Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia

|Jun 13, 2025
Exercise Prescription in Cardio-Oncology.

Nicola Campana, Luca Fazzini, Clelia Donisi

|Apr 14, 2025
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.

Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia

Pageof 4

Frequent Collaborators

14 joint publications

Martino Deidda

6 joint publications

Nicola Maurea

5 joint publications

Luca Fazzini

5 joint publications

Irma Bisceglia